Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Cancer Therapy: Preclinical

BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice

Chengwen Liu, Weiyi Peng, Chunyu Xu, Yanyan Lou, Minying Zhang, Jennifer A. Wargo, Jie Qing Chen, Haiyan S. Li, Stephanie S. Watowich, Yan Yang, Dennie Tompers Frederick, Zachary A. Cooper, Rina M. Mbofung, Mayra Whittington, Keith T. Flaherty, Scott E. Woodman, Michael A. Davies, Laszlo G. Radvanyi, Willem W. Overwijk, Gregory Lizée and Patrick Hwu
Chengwen Liu
Departments of 1Melanoma Medical Oncology and 2Immunology, Center for Cancer Immunology Research; 3Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; Divisions of 4Surgical Oncology and 5Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Weiyi Peng
Departments of 1Melanoma Medical Oncology and 2Immunology, Center for Cancer Immunology Research; 3Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; Divisions of 4Surgical Oncology and 5Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chunyu Xu
Departments of 1Melanoma Medical Oncology and 2Immunology, Center for Cancer Immunology Research; 3Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; Divisions of 4Surgical Oncology and 5Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yanyan Lou
Departments of 1Melanoma Medical Oncology and 2Immunology, Center for Cancer Immunology Research; 3Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; Divisions of 4Surgical Oncology and 5Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Minying Zhang
Departments of 1Melanoma Medical Oncology and 2Immunology, Center for Cancer Immunology Research; 3Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; Divisions of 4Surgical Oncology and 5Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer A. Wargo
Departments of 1Melanoma Medical Oncology and 2Immunology, Center for Cancer Immunology Research; 3Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; Divisions of 4Surgical Oncology and 5Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jie Qing Chen
Departments of 1Melanoma Medical Oncology and 2Immunology, Center for Cancer Immunology Research; 3Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; Divisions of 4Surgical Oncology and 5Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Haiyan S. Li
Departments of 1Melanoma Medical Oncology and 2Immunology, Center for Cancer Immunology Research; 3Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; Divisions of 4Surgical Oncology and 5Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephanie S. Watowich
Departments of 1Melanoma Medical Oncology and 2Immunology, Center for Cancer Immunology Research; 3Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; Divisions of 4Surgical Oncology and 5Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yan Yang
Departments of 1Melanoma Medical Oncology and 2Immunology, Center for Cancer Immunology Research; 3Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; Divisions of 4Surgical Oncology and 5Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dennie Tompers Frederick
Departments of 1Melanoma Medical Oncology and 2Immunology, Center for Cancer Immunology Research; 3Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; Divisions of 4Surgical Oncology and 5Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zachary A. Cooper
Departments of 1Melanoma Medical Oncology and 2Immunology, Center for Cancer Immunology Research; 3Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; Divisions of 4Surgical Oncology and 5Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rina M. Mbofung
Departments of 1Melanoma Medical Oncology and 2Immunology, Center for Cancer Immunology Research; 3Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; Divisions of 4Surgical Oncology and 5Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mayra Whittington
Departments of 1Melanoma Medical Oncology and 2Immunology, Center for Cancer Immunology Research; 3Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; Divisions of 4Surgical Oncology and 5Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keith T. Flaherty
Departments of 1Melanoma Medical Oncology and 2Immunology, Center for Cancer Immunology Research; 3Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; Divisions of 4Surgical Oncology and 5Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott E. Woodman
Departments of 1Melanoma Medical Oncology and 2Immunology, Center for Cancer Immunology Research; 3Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; Divisions of 4Surgical Oncology and 5Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael A. Davies
Departments of 1Melanoma Medical Oncology and 2Immunology, Center for Cancer Immunology Research; 3Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; Divisions of 4Surgical Oncology and 5Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts
Departments of 1Melanoma Medical Oncology and 2Immunology, Center for Cancer Immunology Research; 3Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; Divisions of 4Surgical Oncology and 5Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laszlo G. Radvanyi
Departments of 1Melanoma Medical Oncology and 2Immunology, Center for Cancer Immunology Research; 3Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; Divisions of 4Surgical Oncology and 5Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Willem W. Overwijk
Departments of 1Melanoma Medical Oncology and 2Immunology, Center for Cancer Immunology Research; 3Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; Divisions of 4Surgical Oncology and 5Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory Lizée
Departments of 1Melanoma Medical Oncology and 2Immunology, Center for Cancer Immunology Research; 3Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; Divisions of 4Surgical Oncology and 5Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Hwu
Departments of 1Melanoma Medical Oncology and 2Immunology, Center for Cancer Immunology Research; 3Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; Divisions of 4Surgical Oncology and 5Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1078-0432.CCR-12-1626 Published January 2013
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: November 2012 to February 2021

AbstractFull-text HTMLPDF
Total580351573773

Cited By

Article Information

Volume 19, Issue 2, pp. 393-403

DOI 
https://doi.org/10.1158/1078-0432.CCR-12-1626
PubMed 
23204132

Published By 
American Association for Cancer Research
Print ISSN 
1078-0432
Online ISSN 
1557-3265
History 
  • Received May 18, 2012
  • Revision received November 8, 2012
  • Accepted November 13, 2012
  • Published first November 30, 2012.

Article Versions

  • Previous version (November 30, 2012 - 07:10).
  • Previous version (January 8, 2013 - 09:20).
  • You are viewing the most recent version of this article.
Copyright & Usage 
©2012 American Association for Cancer Research.

Author Information

  1. Chengwen Liu1,
  2. Weiyi Peng1,
  3. Chunyu Xu1,
  4. Yanyan Lou1,
  5. Minying Zhang1,
  6. Jennifer A. Wargo4,
  7. Jie Qing Chen1,
  8. Haiyan S. Li2,
  9. Stephanie S. Watowich2,
  10. Yan Yang1,
  11. Dennie Tompers Frederick4,
  12. Zachary A. Cooper4,
  13. Rina M. Mbofung1,
  14. Mayra Whittington1,
  15. Keith T. Flaherty5,
  16. Scott E. Woodman1,
  17. Michael A. Davies1,3,
  18. Laszlo G. Radvanyi1,
  19. Willem W. Overwijk1,
  20. Gregory Lizée1, and
  21. Patrick Hwu1
  1. Authors' Affiliations: Departments of 1Melanoma Medical Oncology and 2Immunology, Center for Cancer Immunology Research; 3Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; Divisions of 4Surgical Oncology and 5Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts
  1. Corresponding Author:
    Patrick Hwu, Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030. Phone: 713-563-1728; Fax: 713-745-1046; E-mail: phwu{at}mdanderson.org
  1. C. Liu and W. Peng contributed equally to this work.

View Full Text
PreviousNext
Back to top
Clinical Cancer Research: 19 (2)
January 2013
Volume 19, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
Chengwen Liu, Weiyi Peng, Chunyu Xu, Yanyan Lou, Minying Zhang, Jennifer A. Wargo, Jie Qing Chen, Haiyan S. Li, Stephanie S. Watowich, Yan Yang, Dennie Tompers Frederick, Zachary A. Cooper, Rina M. Mbofung, Mayra Whittington, Keith T. Flaherty, Scott E. Woodman, Michael A. Davies, Laszlo G. Radvanyi, Willem W. Overwijk, Gregory Lizée and Patrick Hwu
Clin Cancer Res January 15 2013 (19) (2) 393-403; DOI: 10.1158/1078-0432.CCR-12-1626

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
Chengwen Liu, Weiyi Peng, Chunyu Xu, Yanyan Lou, Minying Zhang, Jennifer A. Wargo, Jie Qing Chen, Haiyan S. Li, Stephanie S. Watowich, Yan Yang, Dennie Tompers Frederick, Zachary A. Cooper, Rina M. Mbofung, Mayra Whittington, Keith T. Flaherty, Scott E. Woodman, Michael A. Davies, Laszlo G. Radvanyi, Willem W. Overwijk, Gregory Lizée and Patrick Hwu
Clin Cancer Res January 15 2013 (19) (2) 393-403; DOI: 10.1158/1078-0432.CCR-12-1626
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Survivin mAbs Inhibit Tumor Growth
  • B7-H3 Negatively Modulates Cancer Immunity
  • RB1 and TYMP as Biomarkers of Capecitabine Response in TNBC
Show more Cancer Therapy: Preclinical
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement